Matthew J. Luneack

Partner

vCard

Matthew J. Luneack

Partner

+1 202 408 4436 +1 202 408 4436
matthew.luneack@finnegan.com matthew.luneack@finnegan.com

901 New York Avenue, NW
Washington, DC 20001-4413

vCard

Show Matthew's work in

Matthew Luneack focuses on patent litigation before U.S. district courts as well as strategic client counseling. His practice covers a variety of technologies, including pharmaceuticals; biotechnology; chemical products and processes; and sports and fitness equipment.

Matthew is involved in all phases of district court litigation, from the initial pleadings through trial and post-trial. His experience includes developing claim construction, infringement, and validity positions; conducting fact and expert discovery; drafting briefs and motion materials; preparing witnesses; taking and defending depositions; arguing claim construction and evidentiary issues; and examining witnesses at trial. Matthew has particular experience representing pharmaceutical patent holders in litigations arising under the Hatch-Waxman Act.

Matthew's counseling practice includes providing strategic advice through opinions of counsel, patent portfolio development and management, due diligence investigations, and freedom-to-operate analyses. He has been recognized by Best Lawyers as "One to Watch."

Prior to his legal career, Matthew gained experience as a research and development intern for Masco Corporation, studying innovative water-saving plumbing products.

Et Cetera

Member, Finnegan's Associate Advisory Committee, 2021-2022.
Capital Pro Bono Honor Roll, 2019.
Managing editor, Vanderbilt Law Review, 2013-2014.
Judicial extern, Honorable Magistrate Judge Mark A. Randon, U.S. District Court, Eastern District of Michigan, Summer 2012.

Experience

Representing Eli Lilly in patent litigations involving antibody therapies.

1:18-cv-12029, D. Mass., Judge Burroughs

Represented Allergan and Pierre Fabre in ANDA litigation in the District of New Jersey against multiple generic drug manufacturers seeking to make a generic version of Fetzima® (levomilnacipran) for the treatment of major depressive disorder.

2:17-cv-10230, D.N.J., Judges Mannion, Salas

Represented Duchesnay in ANDA litigation in the District of Delaware against multiple generic drug manufacturers seeking to make a generic version of Bonjesta® (doxylaine succinate and phyridoxine hydrochloride) for the treatment of nausea and vomiting in pregnancy.

1:18-cv-01895, D. Del., Judges Andrews, Fallon

Represented Bausch Health Companies (f/k/a Valeant), Salix, and Progenics in Hatch-Waxman litigation in the District of New Jersey against concerning ANDA for generic oral versions of Relistor® tablets.

2:16-cv-09038, D.N.J., Judges Chesler, Waldor

Represented Grünenthal in ANDA litigations in the District of Delaware against multiple generic drug manufacturers seeking to make generic versions of Hysingla® ER.

1:15-cv-00687, D. Del., Judges Dyk, Sleet, Stark

Represented Grünenthal in ANDA litigations against several defendants relating to abuse-deterrent formulations of OxyContin^® and Opana®.

1:12-cv-08060, S.D.N.Y., Judges Griesa, Daniels, Gorenstein

Insights

Federal Circuit IP Blog

Assignor Estoppel Has “No Place” in IPR Proceedings Assignor Estoppel Has “No Place” in IPR Proceedings

November 27, 2018

Federal Circuit IP Blog

Federal Circuit Cautions Against Omitting Preamble Transition Words in Claim Drafting Federal Circuit Cautions Against Omitting Preamble Transition Words in Claim Drafting

November 16, 2018

IP Health Blog

CAFC Affirms No Interference-in-Fact in University of California v. Broad Institute CAFC Affirms No Interference-in-Fact in University of California v. Broad Institute

October 9, 2018

Federal Circuit IP Blog

Lack of Reasonable Expectation of Success Prohibits Finding of Interference-in-Fact Lack of Reasonable Expectation of Success Prohibits Finding of Interference-in-Fact

October 4, 2018

IP Health Blog

FDA Draft Guidance on Nonclinical Studies and Labeling for Oncology Therapeutic Radiopharmaceuticals FDA Draft Guidance on Nonclinical Studies and Labeling for Oncology Therapeutic Radiopharmaceuticals

July 19, 2018

Articles

Most-Favored-Licensee Provision Did Not Provide a License to Newly-Acquired Patents or Patents that Did Not Trigger the Provision Most-Favored-Licensee Provision Did Not Provide a License to Newly-Acquired Patents or Patents that Did Not Trigger the Provision

March 7, 2017

LES Insights

News

Press Release

Finnegan Elects Eight New Partners Finnegan Elects Eight New Partners

January 3, 2023

Press Release

29 Finnegan Attorneys Ranked by Best Lawyers

August 18, 2022

U.S. News—Best Lawyers

Press Release

62 Finnegan Attorneys Named to 2019 Capital Pro Bono Honor Roll 62 Finnegan Attorneys Named to 2019 Capital Pro Bono Honor Roll

June 8, 2020

Professional Activities

Virginia Bar Association

Admissions and Education

Admissions

District of Columbia
Virginia

U.S. District Court, D. Delaware
U.S. District Court, D. Massachusetts
U.S. District Court, D. New Jersey
U.S. District Court, S.D. New York

Education

Vanderbilt University Law School: J.D., 2014

University of Michigan: B.S.E., Chemical Engineering, magna cum laude, 2011

Matthew's Practices

Patent Litigation: Branded Hatch-Waxman (ANDA); Patent Trial; Pre-Trial Strategy
Patent Portfolio Management, Monetization, and Transactions: Due Diligence; Opinions and Counseling

Matthew's Industries

Chemicals, Industrials, and Materials: Chemical; Manufacturing
Consumer Goods and Services: Consumer Products
Energy: Oil and Gas
Hospitality, Gaming, and Leisure: Sports, Fitness, and Outdoor Recreation
Life Sciences: Biotechnology; Pharmaceutical

Matthew J. Luneack

Et Cetera

Experience

Insights

News

Professional Activities

Admissions

Education

Matthew's Practices

Matthew's Industries

The Finnegan UPC Hub is a one-stop shop for our insights related to the Unified Patent Court (UPC).